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ABSTRACT
DNA microarrays and RNAseq are complementary
methods for studying RNA molecules. Current com-
putational methods to determine alternative exon us-
age (AEU) using such data require impractical visual
inspection and still yield high false-positive rates. In-
tegrated Gene and Exon Model of Splicing (iGEMS)
adapts a gene-level residuals model with a gene size
adjusted false discovery rate and exon-level analy-
sis to circumvent these limitations. iGEMS was ap-
plied to two new DNA microarray datasets, includ-
ing the high coverage Human Transcriptome Arrays
2.0 and performance was validated using RT-qPCR.
First, AEU was studied in adipocytes treated with (n
= 9) or without (n = 8) the anti-diabetes drug, rosigli-
tazone. iGEMS identified 555 genes with AEU, and
robust verification by RT-qPCR (∼90%). Second, in
a three-way human tissue comparison (muscle, adi-
pose and blood, n = 41) iGEMS identified 4421 genes
with at least one AEU event, with excellent RT-qPCR
verification (95%, n = 22). Importantly, iGEMS identi-
fied a variety of AEU events, including 3′UTR exten-
sion, as well as exon inclusion/exclusion impacting
on protein kinase and extracellular matrix domains.
In conclusion, iGEMS is a robust method for identi-
fication of AEU while the variety of exon usage be-
tween human tissues is 5–10 times more prevalent
than reported by the Genotype-Tissue Expression
consortium using RNA sequencing.
INTRODUCTION
RNA splicing occurs in all-eukaryotic organisms and re-
quires a sophisticated machinery to correctly define exon
boundaries for the removal of introns (1). Splicing can give
rise to diverse transcripts with alternative patterns of exon
inclusion/intron retention altering protein function or post-
transcriptional regulation (2). Alternative splicing (AS) or
alternative exon usage (AEU) occurs in most mammalian
multi-exon genes (3,4) and alterations in AEU has been
linked to a number of diseases, including several cancers (5–
8) and neurodegeneration (9). AEU that lead to pathology,
or altered physiological regulation can be studied using var-
ious global transcriptomics techniques. These include RNA
sequencing (RNA-seq) (10) and DNA microarrays such as
Affymetrix Exon ST arrays (11) andHuman Transcriptome
Arrays 2.0 (HTA 2.0). The Sequencing Quality Control
Consortium (SEQC) recently concluded that deep RNA-
seq in combination with high-resolution DNA microarrays
may provide the most efficient approach for studying the
transcriptome (12), recognizing the complementary nature
of the two technologies. The strength of sequencing tech-
nology is that it aspires to capture the entire diversity of the
transcriptome.
Microarrays have several potential advantages over se-
quencing, particularly for quantifying lower abundance
transcripts. Hybridization technologies typically rely on
greater amounts of cDNA, than RNA-seq. However, the
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array-based detection of each cDNA (or cRNA) is indepen-
dent, so avoiding the competitive detection scenario which
limits the performance of sequencing. For example, the
inability of sequencing low abundance transcripts reflects
highly abundant RNAs accounting for a very large propor-
tion of cDNA library (13) so limiting the diversity of the
library. This limitation will in turn lead to inefficient as-
sessment of the variation in exon use. Using RNA-seq the
Genotype-Tissue Expression (GTEx) consortium recently
concluded that each human tissue transcriptome was de-
fined by relatively few unique genes and surprisingly limited
AEU across tissues (14).
It is plausible that this conclusion reflects technical lim-
itations rather than genuinely sparse use of AEU. How-
ever it may also reflect limitations of the computational
methods used to identify splicing. Indeed most algorithms
for identification of AEU are infrequently utilized because
their performance is suboptimal. For RNA-seq, more fre-
quently used methods include ‘Mats’, (15) or ‘DEXSeq’
which implements a generalized linear model to identify AS
(16). Cufflinks (17) is another commonly used approach fo-
cused on transcript assembly and differential isoform ex-
pression analysis. Unfortunately, none provide clear evi-
dence of yielding a high true-positive detection rate (18) and
therefore improved AEU models are needed.
Surprisingly, entirely satisfactory analytical pipelines for
accurate identification of AEU using microarray data also
remain to be established (18,19). Early pipelines for analy-
sis of data acquired using DNA microarrays include splic-
ing index (SI) (20), Microarray Detection of Alternative
Splicing (MiDAS) (21), Pattern-Based Correlation (PAC)
(22), Analysis of Splice Variation (ANOSVA) (23) and
correlation coefficients (24). More recent methods include
ARH (25), Multiple Exon Array Preprocessing (MEAP)
(26), Corrected Splicing Indices for Exon Arrays (COSIE)
(27) and Finding isoforms using RobustMultichip Analysis
(FIRMA) (28). Given the complexity of the transcriptome
and the substantial potential for generating abundant false
positive results, all of these methods require laborious man-
ual evaluation of the outputs.
The SI method adjusts exon-level expression values
by the corresponding gene-level value and then com-
pares individual exons across two sample classes (20).
MiDAS (See Affymetrix technical support document,
‘exon alt transcript analysis whitepaper.pdf) is conceptu-
ally similarly to SI in as much as it incorporates an anal-
ysis of variance (ANOVA) model across multiple sample
groups. However, as the number of exons per gene increases,
the reliability of MiDAS decreases as it lacks robust control
for multiple testing (25). The most frequently cited method
applied to Exon array data is FIRMA, later adapted to
FIRMAGene for Affymetrix Gene ST platform (28,29).
FIRMA fits a linear model to a composite transcript clus-
ter for each gene, using the residuals to indicate if themodel,
and hence gene, has changed between two conditions. FIR-
MAGene (29) arranges the residual values into genomic or-
der such that persistent and consistent change in residuals
is used to indicate that a particular gene has AEU (as de-
fined by a maximum score per gene), making FIRMAGene
a more powerful model than FIRMA. The FIRMAGene
R package does not, however, adjust for multiple testing (a
non-trivial issue given the impact of gene size), nor does it
identify the precise location of the AEU event(s), making
extensive visual inspection obligatory.
Validation of the aforementioned methods has largely re-
lied on contrasting RNA expression between two diverse
tissues, an extreme scenario of AEU likely resulting in a fo-
cus on easier-to-detect examples of AEU (30). Therefore,
this type of validation provides limited basis to conclude
that an AEU method would be sensitive enough to iden-
tify splicing events within a cell responding to more sub-
tle changes in experimental conditions (31,32). Our aim
was therefore to develop and validate a pipeline that re-
turned a high true positive rate for AEU while being sen-
sitive enough to allow identification of AEU under condi-
tions where the cell is responding to routine experimental
conditions. Here we introduce iGEMS, which is a develop-
ment of the FIRMAGene approach, introducing a gene-size
adapted p-value adjustment in combination with a false-
positive filtered exon level metric that removes the need for
visual inspection. We applied iGEMS to two new DNAmi-
croarray data-sets; a primary adipocyte model treated with
rosiglitazone (ROSI, a PPARG agonist (33)) representing a
typical cell biology experiment and a newly generated inter-
tissue analysis using theHTA 2.0 gene-chip technology. The
technical validation rate was high and iGEMS identified
manymore AEU events than recent RNA-seq based studies
of the human tissue transcriptome.
MATERIALS AND METHODS
Cell culture, drug treatment and cell culture DNAmicroarray
data
Primary adipocyte progenitors were isolated from inguinal
subcutaneous tissue obtained from SV129 and C57BL/6
mice (Harlan, UK). Tissue was processed as previously
described (34–36). Precursor cells were suspended in cul-
ture media and cultured in six-well plates containing Dul-
becco’s modified Eagle’s medium with 10% (vol/vol) new-
born calf serum (Life Technologies), 2.4 nM insulin, 25
g/ml sodium ascorbate, 10 mM HEPES, 4 mM glu-
tamine, 50U/ml penicillin and 50g/ml streptomycin, sup-
plemented or not (as indicated) with 1 M rosiglitazone
maleate (Enzo Life Sciences) from the first day of culture
leading to a robust metabolic phenotype shift in these cells
(35). The cells were cultured at 37◦C in an atmosphere of
5% CO2 in air with 80% humidity. Before harvesting, cells
were examined using phase contrast microscopy (on Leica
DMIRB inverted microscope) to confirm health, while the
media was changed on day one and every second day, but
not on the day the cells were harvested.
Total RNA was isolated from the cultured primary
adipocytes on day 7, using TRizol R© (Life Technologies)
as previously described (37) and quality/quantity was
checked using NanoDrop 2000 spectrophotometer. RNA
was dissolved in 20 l RNAse-free water with no additives.
Affymetrix exon arrays were processed according to the
manufacturer’s protocol. Five microgram of fragmented,
end-labelled sense strand target cDNA was hybridized to
each Mouse Exon 1.0 ST array and a Gene Chip Scan-
ner 30007G was used to scan the arrays (BEA Core fa-
cility, Huddinge Hospital, Sweden). From the 20 RNA
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samples processed, three samples were excluded as outliers
by visually evaluating principal component analysis (PCA)
and normalized unscaled standard error plots prior to any
down-stream analysis. The raw data has been deposited at
GEO (GSE57903).
Human tissue and DNA microarray data
Tissue from monozygotic twin pairs from the FITFAT-
TWIN study (FinnTwin16 Cohort) - a population based,
longitudinal study of Finnish twins born between October
1974 and December 1979 was used in this study (38). Se-
lection of the twin pairs for the FITFATTWIN study was
performed on the basis of a web-based questionnaire sur-
vey to the cohort (39), telephone interview, interview at the
laboratory and medical examination at the laboratory (40).
The participants had no chronic disease affecting the ability
to exercise, no acute disease and no drug or alcohol abuse
and thus can be considered healthy (Table 1). All experi-
mental procedures and study protocols were approved by
the Ethical Review Board for Human Research of the Cen-
tral Finland Health Care District (29 September 2011) and
the study was conducted in accordance with the Declara-
tion of Helsinki. All participants volunteered and provided
written informed consent.
Various clinical parameters were collected, as previously
described (40). Briefly, measurements of physical fitness,
body composition (including fat percentage measured by
dual-energy x-ray absorptiometry, (DEXA) and blood sam-
ples including glucose homeostasis from an oral glucose tol-
erance test) were collected. Body composition data included
BMI (mass (kg) / height (m)2) and waist circumference.
Whole body DEXA was performed (DEXA Prodigy; GE
Lunar Corp., Madison, WI, USA) to estimate lean tissue
and body fat mass. VO2max (ml/min) was determined by
bicycle ergometer exercise test using the mean of the two
highest 30s recordings at the end of the max test. Vmax
spiroergometer (Sensormedics, Yorba Linda, CA, USA)
was used to measure oxygen uptake and gaseous exchange.
Supine blood pressure (mmHg) was recorded in the morn-
ing prior to VO2max test, during VO2max test and at 2 min
intervals during recovery. Fasting blood samples were taken
following an overnight fast and 10 min of supine rest upon
arrival. Participants then underwent a 75 g oral glucose tol-
erance test with blood(s) samples taken at thirty minutes,
1 and 2 h post glucose load. Serum glucose and insulin
levels were measured by Konelab 20 XT (Thermo Fisher
Scientific, Vantaa, Finland) and IMMULITEO` 1000 Ana-
lyzer (Siemens Medical Solution Diagnostics, Los Angeles,
CA, USA) respectively.Metabolic health was defined by the
homeostatic model assessment (HOMA) (41).
Blood (PaxGene), muscle and fat were collected for RNA
isolation. Procedures for taking the muscle and adipose tis-
sue biopsies were as before (42), with tissue samples taken
after an overnight fast between 8 and 10 am under local
anesthesia. The muscle biopsy was taken from the mid-part
of m. vastus lateralis using a Bergstro¨m’s needle (ø5 mm)
and a needle biopsy (12 G needle, ø2 mm) of subcutaneous
abdominal adipose tissue was taken at the level of the um-
bilicus. The samples were cleaned of any visible connective
tissue and muscle samples were cleaned of any visible adi-
pose tissue. One part of each tissue biopsy was frozen in liq-
uid nitrogen immediately after withdrawing from the needle
and stored at−80oC until used for analysis. For the twin tis-
sue (muscle, blood and adipose) gene-chip analysis, RNA
was isolated using TRizol R© (Life Technologies) as previ-
ously described (37) and quality/quantity was checked us-
ing NanoDrop 2000 spectrophotometer (Labtech Interna-
tional, UK). RNA was dissolved in 20 l RNAse-free wa-
ter (Life Technologies) with no additives. Affymetrix HTA
2.0DNAmicroarrays were processed according to theman-
ufacturer’s protocol. Five microgram of fragmented, end-
labelled sense strand target cDNA was hybridized to each
DNA microarray and a Gene Chip Scanner 30007G was
used to scan the DNA microarrays (Affymetrix Core, MPI
A/S, Denmark). From the 70 RNA samples processed, nine
samples were excluded as outliers by visually evaluating
PCA and normalized unscaled standard error plots prior to
any down-stream analysis. The raw data has been deposited
at GEO (GSE73142). For the purposes of the present analy-
sis we did not implement use of the twin structure (each pair
were discordant for environmental factors) as we focused on
paired tissue comparison within individuals.
Description of the iGEMS multi-step alternative exon usage
identification pipeline
Aroma.affymetrix (43) and Bioconductor (44) packages
were used to develop an integrated pipeline for ‘automated’
identification of AEU (Figure 1). The strategy was to pro-
duce gene-level and exon-level based ranking of genes, while
adjusting for multiple testing. The aim was to yield a high
true positive rate for selected AEU events while limiting ad-
hoc or complex heuristic-sensitive filtering processes. The
procedure for implementing FIRMAGenewas adapted (29)
for use with Exon Array ST arrays and an updated CDF
(chip definition file), representing Ensembl gene identifiers,
was sourced from BrainArray (45) (Figure 1). Probes were
arranged in genomic order and probe-set expression values
were calculated using RMA (46). Probe-sets with less than
three probes were removed from the analysis as these are
not considered to provide a very reliable measure of tran-
script expression. The equations detailing theRobinson and
Speed FIRMAGene model (29) are shown in Supporting
File: Supporting Information 1.1. In contrast to the origi-
nal implementation, we used median residual values, rather
than standardized residuals, to estimate deviation from the
FIRMAGene model across biological replicates as median
is more robust to the influence of outliers. The maximum
absolute partial sum of residues is computed per gene, a pa-
rameter defined by Robinson et al. to as the ‘Material Un-
accounted For’ (MUF) score (28).
The difference between the median residual values be-
tween two conditions (e.g. control versus ROSI treated pri-
mary adipocytes) reflects, in our study, the impact of drug
treatment on AEU, and a high absolute MUF score indi-
cates stronger gene-level evidence for AEU. However, as the
number of probes per gene increases, there are more partial
sums to consider and more extreme MUF values will occur
by chance. We therefore implemented a false discovery rate
(FDR) approach (47). Empirical distributions ofMUF val-
ues, for different numbers of probes, were achieved by ran-
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Table 1. Twin study clinical characteristics
Mean ± SD Min Max
Age (y) 34 ± 1.45 32 37
Height (cm) 1.78 ± 0.07 1.6 1.9
Weight (kg) 76.51 ± 9.8 51.3 95.9
Body mass index (kg/m2) 24.12 ± 2.7 19.8 33.6
Waist circumference (cm) 86.19 ± 7.8 70.5 111.5
Fat percent (%) 21.47 ± 6.8 7.7 35.9
Systolic blood pressure (mmHg) 113.34 ± 9.9 94 140
Diastolic blood pressure (mmHg) 68.8 ± 7.5 50 80
Fasting glucose (mmol/l) 5.47 ± 0.5 4.7 6.6
Fasting insulin (U) 3.85 ± 3.2 0.2 14.6
HOMA index 0.96 ± 0.87 0.04 4.3
A summary of the clinical characteristics of the male monozygotic twins (n= 14) with adipose, muscle and blood samples that were profiled on the human
transcriptome 2.0 array.
Figure 1. Schematic diagram of iGEMS pipeline for the identification of alternative exon usage (AEU). iGEMS integrates analysis at both at the gene (blue
boxes) and at the exon level (red boxes). An optional filter based on standard deviation can be applied to remove genes likely to be non-expressed which is
important in scenarios where gene expression is absent in one condition. At the gene level we calculate the FDR for the adjusted Material Unaccounted
For (MUF) score. Genes with significant MUF score (FDR < 1%) are analysed further (Step 1). To locate the AEU within candidate genes (i.e. genes with
a significant absolute MUF score) we calculate a splicing index (SI) per exon. Genes with at least one exon with an SI value in the top or bottom decile
of the SI distribution of the Step 1 filtered data are selected (Step 2). In the third iGEMS step we apply a ‘negative selection’ filter, which identifies exons
as false positive AEU events if expression of the exon, in both the control and treatment groups, is lower than the median gene expression for respective
conditions, and where the associated Limma based FDR indicates that the respective exons are not differentially expressed (FDR > 1%) (Step 3). This
yields a modest filtering of the genes selected at steps 1 and 2 (FDR adjusted MUF scores and SI ranked list) and results in a list of genes that undergo an
AEU.
PAGE 5 OF 14 Nucleic Acids Research, 2016, Vol. 44, No. 11 e109
domly sampling from all available residuals (so adjusting
for ‘gene size’ (variations in exon number)). FDR values for
experimentally observed MUF scores can then be derived
by calculating the probability of obtaining an identical or
more extreme MUF score from the empirical distribution.
This was implemented using the ‘stats’ package inR, and an
FDR threshold is then chosen above a given quantile (e.g.
1%FDR). This represents ‘Step 1’ in theAEU identification
(Figure 1).
However, identification of a gene with a significant MUF
score does not identify the AEU event. For this we imple-
mented the SI method (equations for this method in Sup-
porting File: Supporting Information 1.1, adapted to in-
clude a false positive filter (See below)), to identify the likely
location of an AEU event. Incorporation of this measure
allows ranking of exons within genes that have a significant
MUF score. In the cell culture experiment, genes with an
SI value in the top or bottom decile of the SI distribution
represents the second step of AEU identification (denoted
as ‘Step 2’ in Figure 1). As this was a method development
project, visual validation was used to evaluate performance
and thus expression values and residual plots were gener-
ated for genes that passed the step 1 and 2 criteria (Figure
1). Biomart (48) was used to link expression data to the lat-
est version of identifiers in Ensembl while RMAnormalized
data and residuals were plotted using the ‘GenomeGraphs’
package.
During the visualization validation process we noted
genes with robust MUF and SI scores originating from
exons where the preceding exons in both the control and
drug-treated groups had expression values that approxi-
mated background. A simple ‘detected as expressed’ filter,
which attempts to estimate a threshold for background ex-
pression (49), removed a substantial number of true AEU
events and thus was not useful. Instead, an exon-level fil-
ter was developed where lack of differential exon expres-
sion (50) between the two groups on the AEU location was
used to detect the aforementioned class of false positives.
More specifically, for a false positive SI event, we identi-
fied exon(s) where expression in both the control and treat-
ment groups was lower than themedian gene expression and
where the exon preceding the significant SI event was not
differentially expressed between conditions (e.g. >1% FDR
in the present dataset, using limma). This reduced the num-
ber of genes identified from the FDR adjusted MUF score
and SI ranked list (i.e. AEU identification steps 1 and 2) by
∼25%. This step is denoted as ‘Step 3’ in Figure 1. Con-
vincingly, visual inspection of a large sample of the genes
removed by the third step indicated removal of >90% gen-
uine false positives (also supported by RT-qPCR (see re-
sults)). Finally an optional low-level filter to eliminate non-
expressed genes can be implemented using a small absolute
value for gene expression standard deviation (SD), with the
value chosen reflecting the individual gene-chip and exper-
imental characteristics (See tissue analysis section below).
Experimental validation of murine AEU events by RT-qPCR
For RT-qPCR 500 ng of total RNA was reversed-
transcribed with the High-Capacity cDNA Reverse Tran-
scription kit (Life Technologies) according to manufac-
turer’s protocol. cDNA was diluted 1:5 and 1 l was added
per well to 384-optical well plates (Life Technologies). Exon
specific primers (Sigma-Aldrich) were designed for genes se-
lected from the first 100 ranked genes, with Primer-BLAST.
Primers were mixed with SYBR Select Master Mix (Life
Technologies) and aliquots of 11 l of mastermix were
added to each well. Samples were run in triplicate. Thermal
cycling conditions were 2 min at 50◦C followed by 2 min at
95◦C, and 40 cycles of 15 s at 95◦C and 60 s at 60◦C on a
ViiATM 7 Real-Time PCR System (Life Technologies). To
control for RNA input, 18S levels were measured using an
Eukaryotic 18S rRNA Endogenous control kit (Life Tech-
nologies) according manufacturer’s protocol with 1:200 di-
luted cDNA. Target mRNA expression was quantified us-
ing the CT method (51). For each gene an AEU exon and
an exon deemed constitutively expressedwasmeasured. The
data is presented as percentage change (%) from control.
To determine the statistical significance a Mann–Whitney
U test was preformed on the Ct values followed by Bon-
ferroni correction. Primers used for the murine Exon ar-
ray RT-qPCR validation can be found in Supporting File
2: Supplementary Table S1. Transcript variants were visu-
alized using GPViz (52). Methods for HTA 2.0 RT-qPCR
validation can be found in Supporting File 1: Supporting
Information 1.2.
Functional characterization of AEU
There are limitations to the usefulness of pathway or gene
ontology (GO) analysis for identifying enrichments of bi-
ological functions among genes in a list of regulated genes
(53). The ‘regulated gene list’ (in this case genes with AEU
events) must be contrasted with a list of the detectable genes
in the experiment (and not all the genes in the genome or
on the gene-chip) (32,54). We analysed the list of genes
containing AEU events to determine if that list was en-
riched in GO categories that either supported the known
biological differences between any two tissues, or included
molecular functions related to functional protein features
(as exon removal/inclusion is proposed to alter protein
structure/function). We utilized GOstats package in R with
current GO categories (GO.db) to examine GO hierarchy
and identify the point of greatest enrichment using R (55).
We characterized the impact of the change in protein se-
quence, brought about by AEU. The exon in each signifi-
cant gene, with the most positive and most negative SI, was
mapped to amino acid ranges using the expected products
of coding transcripts. The exon based amino acid ranges
were then overlapped with Pfam domain positions (i.e. en-
velope start, envelope end) using data from Pfam release
29 (56). The Pfam domain frequency was plotted for each
inter-tissue comparison.
RESULTS
Implementation of iGEMS pipeline using the Affymetrix
EXON ST platform
For development of iGEMS we generated a dataset con-
trasting cells with or without ROSI treatment (see meth-
ods), i.e. where more subtle changes in AEU are ex-
pected as compared to comparisons between diverse tis-
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sues. The outline of the iGEMS pipeline is shown in Fig-
ure 1 and summary statistics of the processing of transcrip-
tomics data in Table 2. The R script for each chip-type
specific iGEMS pipeline is provided at https://github.com/
iaingallagher/iGEMS scripts. The MUF scores and the as-
sociated FDRs for each gene were calculated, contrasting
control with ROSI treatment. As expected the relationship
of FDR toMUF scores did not follow a simple linear trend
because, depending on the number of probes for a gene, a
specific MUF score will be associated with different FDRs
(Figure 2A). We selected those genes with a MUF score as-
sociated FDR<1% (Figure 2A). This resulted in a list of
1464 genes with evidence for AEU in response to ROSI.
To identify which exons are responsible for these gene-level
scores, we calculated the SI for each of the 22 652 exons
present in our candidate 1464 gene list. Approximately 50%
of the genes with significantMUF scores also contained ex-
amples of exons with more extreme SI scores (n= 729,<1%
FDR, Figure 2B).
Figure 3A shows the residual plots for Agpat1 (ENS-
MUSG00000034254) with a strong spike in residuals to-
wards the 5′ end of the gene (black arrow). The relatively
simple task of identifying AEU in Agpat1 can be con-
trasted with Ptprd (Supplementary Figure S1) where visual
inspection is not practical. We selected Agpat1 and six ad-
ditional genes for RT-qPCR validation. An extreme SI was
used to select the exon(s) undergoing AEU and this was
contrasted with an exon that had relatively stable expres-
sion between groups (Figure 3B). For Agpat1 RT-qPCR
primers were designed (Supporting File 2: Supplementary
Table S1) to target exon ENSMUSE00000934556, the AEU
exon, while a second set of primers targeted to Exon ENS-
MUSE00000707276 (blue box), the constitutively expressed
exon (Figure 3B and C). Indeed RT-qPCR confirmed that
ENSMUSE00000934556 was subject to AEU by ROSI
(Figure 3B, increased ∼5 CT values, P = 0.0004) while the
constitutively expressed exon remain unchanged. It should
be noted that the accompanying plot of exon expression
values, derived from microarray data are not corrected for
probe-characteristics (e.g. nucleotide composition etc.) and
thus absolute expression values are not directly comparable
across exons.
The same approach was applied to six additional genes
(Figure 4 and Supplementary Figure S2; exon expression
values are shown in Supplementary Figure S2) identified by
the first two steps in our pipeline and all but one validated.
Thus, we validated Pde4dip (ENSMUSG00000038170,
Figure 4A), Rapgef5 (ENSMUSG00000041992, Fig-
ure 4B) Akt2 (ENSMUSG00000004056, Figure 4C),
Clstn3 (ENSMUSG00000008153, Figure 4D) and Xrcc6
(ENSMUSG00000022471, Figure 4E). Rxrg (ENS-
MUSG00000015843, Supplementary Figure S3) failed to
validate and the residual plot for Rxrg demonstrated a high
MUF score (Supplementary Figure S3A) coupled with
changes in global expression, but not at the 5′ end as there
was an apparent lack of expression of the 5′ exons (red box,
Supplementary Figure S3B). RT-qPCR confirmed that the
proposed AEU event was a false positive, caused by the 5′
part of the signal approximating background expression i.e.
not expressed (e.g. RT-qPCR CT values >37). In contrast,
ENSMUSE00000687625 (blue box, Supplementary Figure
S3B) was robustly expressed and increased in response to
ROSI treatment (P = 0.0002).
Thus sequential changes in exon expression preceded by a
‘signal’ from non-expressed can lead to false positive AEU
events. As a general solution for this problem we applied
a negative selection criterion as described above (Step 3,
an exon level false positive filter (Figure 1). We confirmed
that this simple filter accurately removed∼90%of such false
positives, including Rxrg, using extensive visual inspection,
yielding a final list of 555 AEU genes from the original list
of 729 (Table 2). Notably, none of the laboratory validated
AEU events were removed by this Step 3. In summary, by
combining gene level and exon level analysis with a simple
filter for non-expressed probe-sets, iGEMS efficiently iden-
tified AEU with a low occurrence of false positives, our pri-
mary aim. iGEMS is not specifically optimised for identi-
fication of all true-positives, as such an aim will be more
heavily influenced by sample size and size effect (the magni-
tude of AEU).
Application of the iGEMS pipeline to Affymetrix human tis-
sue array 2.0 data
Analysis of muscle, adipose and blood samples using the
HTA 2.0 array allowed for a direct comparison with GTEx
consortium transcript diversity analysis (14) of these same
tissues. Our samples originated from monozygotic twins
(40) of a very similar age (∼33 years) and in good health
(n = 14, Table 1). Mele et al. (14) report that there was lim-
ited evidence of AEU between most human tissues. As dis-
cussed above, however, this may reflect specific features of
the RNA-seq data and/or limitations of the methodologies
available for identifying AEU. We revisited this issue by ap-
plying the iGEMS pipeline to pairwise comparisons to three
of the human tissues in their analysis (adipose, blood and
muscle).
Since cross tissue comparisons will include many exam-
ples where the entire transcriptional unit is expressed in only
one tissue, we implemented an SD filter to remove genes
based on a low and invariant expression signal. This SD step
was used prior to step 1 of the iGEMS pipeline for analysis
of the Affymetrix HTA 2.0 array across the paired compar-
isons. To select a suitable SD filter value (in this case SD =
3) we plotted the distribution of SD values. The relationship
between expression and tissue identity was examined using
PCA. We demonstrated that genes preferentially expressed
in blood, separated blood samples frommuscle and adipose
(which co-clustered). GO analysis of the preferentially de-
tected genes, for example blood versus muscle, confirmed
that the gene lists contained the expected biological profiles
(Supplementary Table S2). A biologically informative pro-
file was apparent even when utilizing the lowest quartile for
expression values for genes preferentially expressed in tissue
suggesting that the SD threshold of three expression units
for ‘detected’ left intact low expressed genes (Supplemen-
tary Figure S4). We detected a combined total of 25 338
genes with median expression above this background (>3
SD expression units) in human adipose, muscle and blood
i.e. more than gene detection counts with RNA-seq in these
three tissue, even when a favourable filter (towards RNA-
seq) for ‘detection’ was considered (e.g. >0.1 RPKM in at
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Figure 2. Distribution of absolute MUF scores (step 1) and SI (step 2) in adipocytes treated with rosiglitazone and profiled using Affymetrix Mouse Exon
1.0 DNAmicroarrays. (A) The distribution of MUF scores (absolute) and the corresponding FDR values. The red and blue line represents the 1% and 5%
FDR cut-off values respectively. Using the 1% cut-off we identified 1464 genes to have significantMUF score. (B) Shown is the distribution of SI calculated
at the exon-level for all exons. Using the exons from the 1464 candidate genes (∼22 652 exons) we apply the upper and lower decile for the SI cut-off as
−0.635 and 0.646 respectively. This resulted in 2266 exons (red bars) passing step 2 (Figure 1), which corresponded to 729 genes as candidates for AEU.
Table 2. Summary statistics of the alternative exon usage (AEU) pipeline on Mouse Exon 1.0 ST array
Group Filtering steps of iGEMS Genes or exons
A Number of exons annotated on array 325 446
B Number of genes annotated on array 26 500
C Number of genes with <5% FDR 4688
D Number of exons represented from C 69 253
E Number of genes with <1% FDR 1464
F Number of exons represented from E 22 652
G Number of genes from E within 10% SI distribution 729
H Number of exons from F within 10% SI distribution 2266
I Number of genes after removing false positives from G 555
J Number of exons after removing false positives from H 1677
Flow of the transcriptomic data through the stages of the analysis workflow, starting with all the probe-set features on the Mouse Exon 1.0 ST array
measured using gene and exon BrainArray CDF files. Using the AEU pipeline on the murine primary adipocyte gene- and exon-level expression data, a
final list of 555 genes with evidence for AEU was identified.
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Figure 3. Identification of Agpat1 undergoing an AEU event in response to rosiglitazone (ROSI). (A) The MUF score is derived from the residual plot
of Agpat1 (ENSMUSG00000034254). Residual values were plotted in genomic order with the composite gene structure juxtaposed below. Our analysis
was performed on eight control (light blue) and nine ROSI treated cell cultures (dark blue). Blue lines connect the residual value to their respective
genomic regions. Towards the 5′ end of Agpat1 there was a high deviation from the model indicating an AEU event (black arrow). (B) Expression plot
of the mean expression intensity (±standard deviation (SD)) of each Ensembl exon ID assigned to Agpat1; light blue represents the control and dark
blue the ROSI treated values. Ensembl Exon ID ‘ENSMUSE00000934556′ is the AEU exon (red box) and ENSMUSE00000707276 (blue box) is the
constitutively expressed exon. Primers were designed to independently measure these two exons. RT-qPCR validation was carried out in independent
RNA (mean ± SD; control (n = 8) and rosiglitazone (ROSI) (n = 9)) and is shown as percent (%) change from the control group with ROSI with the
colour consistent with the exon ID plot on the left. CT values and adjusted P-values are shown for the control and ROSI group. (C) Schematic of the
two Agpat1 variants: a full Agpat1 variant (ENSMUST00000037489, lower panel) which does not contain the AEU exon we identified, and the truncated
Agpat1 (ENSMUST00000173242, higher panel) which contains the AEU exon. The highlighted exons (red and blue) represent the AEU exon and the
constitutively expressed exon, respectively as measured by the array and the RT-qPCR primers. Exons part of the translated RNA is represented as a thick
box than untranslated.
least 25% of samples) see Supporting File 2: Supplementary
Table S3.
In total there were 4421 genes with significant AEU
events across pairwise comparisons of the three tissue types
using the HTA 2.0 arrays (Supporting File 2: Supplemen-
tary Table S4). This is ∼5–10× more than Mele et al. ob-
served in their pairwise analysis between the same tissues.
To confirm that this reflected a high true positive rate we
visually inspected AEU in 100 gene expression plots be-
tweenmuscle and adipose tissue with FDR values<5% and
used RT-qPCR to validate AEU events (Figure 5 and Sup-
plementary Figure S5, see Supporting File 2: Supplemen-
tary Table S5 for primers used).Most AEU events validated
(∼95%) and involved of a variety of types of AEU events in-
cluding exon inclusion/exclusion (Figure 5A), alternative 3′
UTR utilization (Figure 5B), 3′ UTR extension (Figure 5C)
and mutual splicing events (Figure 5D). The very high val-
idation rate in our study may reflect the conservative MUF
and SI thresholds we selected. A proportion of genes had a
significant MUF score but did not contain an exon with an
extreme SI value (Supplementary Figure S6) but there were
few true positives below our selected thresholds (according
to visual inspection). Selecting an acceptable SI threshold
will be study specific, in our case the criteria selected did
not compromise identification of a high true positive rate
and yields a high number of detectable events.We also noted
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Figure 4. Validation of five AEU events by visual inspection and RT-qPCR. For each gene, a schematic of the transcript(s) is shown with red and blue
boxes highlighting the AEU exon and constitutively expressed exon, respectively (targeted by RT-qPCR primers). Exons part of the translated RNA is
represented as a thick box than untranslated. RT-qPCR data is shown as percent (%) change from the control group (n = 8) with rosiglitazone (ROSI) (n
= 8) (mean ± standard deviation) with the colour consistent with the Exon ID plot above. The expression of AEU exon changed relatively more than the
constitutively expressed exons, in response to ROSI treatment. (A) Pde4dip (ENSMUSG00000038170), (B) Rapgef5 (ENSMUSG00000041992), (C) Akt2
(ENSMUSG00000004056), (D) Clstn3 (ENSMUSG00000008153) and (E) Xrcc6 (ENSMUSG00000022471).
that for muscle∼15% of AEU events identified appeared to
be driven by contamination of the muscle ‘signal’ by genes
highly expressed in blood, rather than genes genuinely ex-
pressed in muscle (reflecting modest blood contamination
of muscle biopsies).
To characterize the potential impact of these events, genes
undergoing AEU between tissues were subjected to GO
analysis, identifying molecular functions associated with
each pairwise comparison (Supporting File 2: Supplemen-
tary Table S6) e.g. actin binding and microfilament activity
between muscle and blood. Further, protein domain analy-
sis was performed to determine the frequency of Pfam do-
mains present within exons undergoing AEU in each pair-
wise comparison (Figure 6), with the most common Pfam
domains being individually listed (Supporting File 2: Sup-
plementary Table S7).
DISCUSSION
Alternate exon usage modifies protein biochemical func-
tion, diversifying canonical pathways and represents an im-
portant contributor to cell phenotype. Methods developed
to detect differential splicing using DNA microarrays have
lacked acceptable true positive rates, or clear guidelines for
appropriate implementation. Here we introduce an AEU
identification process that has a robust performance with
minimal heuristics and robust control for multiple testing.
Rather than limiting discovery of AEU events we demon-
strate that exon focusedDNAmicroarrays detect thousands
of AEU events between human tissues, in contrast with
analysis of the human tissue transcriptome using RNA-seq
(14). As can be observed in Figure 6, a core of AEU events
and modified Pfam categories are shared across each tis-
sue pairing (e.g. muscle versus adipose and adipose versus
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Figure 5. iGEMS identified diverse types of AEU events between muscle and adipose with RT-qPCR validation. We utilized the Affymetrix HTA 2.0 array
to analyse tissue samples in a pairwise manner. Here we show four examples of different types of AEU events. Each accompanied with their respective linear
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blood) was substantial enough to suggest that AEU con-
tributes substantially to tissue specialization. Within the
limited number of genes with AEU identified by Mele et al.
(14)<20% overlapped with the present analysis. Not unsur-
prisingly, the overlap was biased towards genes with greater
than average RPKM units (Supplementary Figure S7), in-
dicating that lack of robust quantification of RNA abun-
dance by RNA-seq may explain the failure to note substan-
tially amounts of AEU. In contrast, arrays identified AEU
across the expression value continuum, with only a modest
bias for genes with higher expression signal.
Using adipocytes treated with the anti-diabetic drug,
rosiglitazone, Agpat1 underwent AEU. Agpat1 belongs to
the 1-acylglycerol-3-phosphate O-acyltransferase protein
family which are involved in phosphatidic acid produc-
tion, which is an intermediate step in triglyceride synthe-
sis (57). According to Ensembl, ENSMUSE00000934556 is
a non-coding exon that appears exclusively in the shorter
transcript: (ENSMUST00000173242, Figure 3C). Whereas
ENSMUSE00000707276, the exon unique to the full vari-
ant, had a much lower CT (i.e. detected earlier in the RT-
qPCR assay), consistent with the view that it is the dom-
inant RNA variant (58). The regions absent in truncated
Agpat1 contain motifs III and IV, which are required for
acyl-CoA binding and catalysis, and LPA binding (59). The
shorter transcript (ENSMUST00000173242), with this al-
ternative 5′ UTR, could yield a protein with distinct bio-
chemical function due to loss of substrate binding site and
hence loss of substrate level regulation of enzyme activity.
Functional analysis of the inter-tissue analysis also revealed
the expected biological narrative e.g. muscle included a va-
riety of modifications to contractile proteins when com-
pared with blood (Supporting File 2: Supplementary Ta-
ble S6). Pfam domain analysis revealed that ‘EGF C’ was
most frequently modified functional motif between adipose
and blood, while ‘PKinase’ protein kinase Pfam domain
was common modified when comparing muscle with either
blood or adipose tissue (Figure 6, Supporting File 2: Sup-
plementary Table S7).
Previously published AEU pipelines appear optimized to
single experimental designs or lack any laboratory valida-
tion. For example, PAC detects splice variants on the as-
sumption that exon expression tends to follow the gene ex-
pression across the samples if there is no alternative splic-
ing (22). PAC needs at least three distinct groups to derive a
meaningful model and it fails when applied to the compari-
son of two conditions (28) and in our adipocyte experiment.
Approaches such as the ‘SI method’ (20) and the conceptu-
ally similarMiDASwhich usesANOVAorANOSVAwhich
fits a linear model to the observed data with the aim of iden-
tifying non-zero interaction terms between sample groups
and exons (23), have all been found to be unreliable. Criti-
cally, as the exon number increases the detection ability of
statistical tests likeMiDAS andANOSVA decreases as they
do not accurately correct for multiple testing (25).
IGEMS ranks genes both at a gene-level and at the exon
level (Figure 1) providing direct information on which par-
ticular exon(s) are likely to be undergoing AEU within a
gene that is first ranked to contain a significant AEU event
by Step 1. Given that the HTA 2.0 array detected the ex-
pression of>25 000 ‘genes’ (coding and non-coding) across
the three tissues profiled in the present study, it is clear that
an automated pipeline is essential to study AEU using such
technologies. IGEMS incorporates the FIRMAGenemodel
(albeit with a modified statistic) using it for the first time
with exon and ‘tiling’ type arrays. McGlincy et al. (60) used
the original FIRMAGene method to examine the impact of
the circadian cycle on AEU coupled with ANOVA to iden-
tify AEU. To improve true positive detection they used only
the core probe-set (‘best’ annotated) map of the EXONmi-
croarray. However, they could only validate ∼50% of the
highest ranked genes, by RT-qPCR. In contrast we vali-
dated >90% of our findings from the mouse EXON array
using RT-qPCR (genes selected from the first 100 in or-
der). Further extensive RT-qPCR of an additional 22 exam-
ples of AEU (with genes being selected from MUF scores
ranked 18–1514th) from the HTA 2.0 twin tissue analysis
yielded a 95% validation rate. This indicates that we have
achieved a significant improvement in performance over all
existing AEU analysis pipelines to yield a high true positive
rate.
However, it is also important to consider why we were
able to identify far more AEU between tissues than Mele
et al. (14) using a similar number of biological samples.
They determined when internal cassette exons were prefer-
entially used with the ‘Percent Spliced-in’ (PSI) approach
(61,62) applied to RNA-seq data. In doing so they con-
cluded that variation in expression rather than variation in
splicing explained tissue diversity. Despite their RNA-seq
and our HTA analysis detecting a similar number of tran-
scripts (14) we found ∼5–10× more AEU across human
tissue types (their threshold for detection was rather gen-
erous). PSI in its simplest form is a ratio metric of reads
that include the cassette exon versus reads that include
or exclude the respective exon. Differences at a particular
threshold on this ratio metric scale are considered to de-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
expression intensities from the microarray analysis (mean ± SD). From a total of 14 pairs of twins, quality control validated paired microarray analysis
was carried out on muscle (red, n= 12) and adipose (black, n= 12). RT-qPCR validation was carried out in remaining RNA (mean ± SD; muscle (n= 14)
and adipose (n = 9)) and is shown as percent (%) change from adipose to muscle tissue with the colour consistent with the Exon ID plot on the left. (A)
TMEM245 (ENSG00000106771) undergoes an exon exclusion event in muscle as Ensembl Exon ID ENSE00001181383 is expressed much lower in muscle
than adipose tissue. This AEU event was not evident in the ensembl database, but was represented in the NCBI database. (B) SRSF5 (ENSG00000100650)
undergoes an alternative 3′ UTR event in muscle and at least two SRSF5 transcript variants exist: ENST00000557154 (full) and ENST00000553369
(truncated), with the latter transcript containing Ensemble exon ID ENSE00002452925 which was expressed in muscle to a greater extent. (C) CCDC47
(ENSG00000108588) undergoes 3′UTR extension in adipose tissue since Ensembl exon IDENSE00001347617 (probes span the entire 3′UTR)was detected
in adipose more thanmuscle. (D)RAB6A (ENSG00000175582) undergoes amutual splicing event which produces at least two transcripts, with each variant
containing a mutually exclusive exon; ENSE00001358762 which is expressed more in adipose tissue (part of ENST00000310653) while the other exon
(ENSE00001184543) was is expressed more in muscle tissue (part of ENST00000336083). Details on RT-qPCR validation applied to the human tissue can
be found in Supplementary Figure legend S5 and Supporting Information 1.2.
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Figure 6. Frequency of Pfam domains altered by AEU across muscle, adi-
pose and blood. Each chart represents a single pairwise comparison. Over-
lapping Pfam domains within Ensembl exon ID coordinates are counted.
Only the most frequently occurring Pfam domain classes are shown indi-
vidually while remaining classes are summed in the ‘other’ group. (A) For
blood versus adipose, the Pfam domain is listed if it occurred ≥ 3. (B) For
adipose versus blood, the Pfam domain is listed if it occurred ≥ 3. (C) For
blood versus muscle comparison, the Pfam domain is listed if it occurred
≥ 9.
tect spliced exons. In comparison, the first step in iGEMS
does not compare individual exons, but looks for small con-
tinuous changes along a gene. Also the PSI approach re-
quired two constitutively expressed flanking exons to iden-
tify the potentially spliced exon implying their method was
biased towards central cassette exons, unlike iGEMS which
identified a variety of AEU events, including alternative 3′
UTR utilization (Figure 5B). Further, since we observed
that genes subject to AEU were also frequently (60–80%
of those identified) differentially expressed, an accurate es-
timation of the contribution of expression versus AEU to
inter-tissue variance is not necessarily a meaningful anal-
ysis, in our opinion. Clearly membership of each category
would reflect the statistical thresholds chosen for AEU or
differential expression in the experiment.
Data modelling considerations aside, we demonstrated
that using a non-competitive detection system i.e. a DNA
gene-chip (i.e. each converted/labelled ‘RNA’ is detected in-
dependently from each other) yields a rich view of the tis-
sue transcriptome. Thus, DNA microarray technologies re-
main a very useful and complementary technology (12,13)
to RNA-seq technologies, with the advantage that it is more
reproducible (technical replicates R2 > 0.95 compared to
R2 < 0.9 for RNA-seq (10,12)) and still more cost-effective,
particularly in terms of data processing and data storage.
Indeed, according to the SEQC the coverage and perfor-
mance achieved with the latest HTA 2.0 DNA microar-
rays requires ∼100 million aligned reads per sample for
the equivalent information to be yielded by RNA-seq (12).
Given that Mele et al. report ∼80 million aligned reads per
sample and still identified ∼5–10× fewer AEU events than
the present study, this value for ‘equivalence’ may be a sub-
stantial under-estimate. For example, the number of read-
alignments required for blood and muscle may substan-
tially exceed 100 million, as we noted limited co-linearity
between sequencing depth and number of detected low ex-
pression genes in blood and muscle tissue (Supplementary
Figure S8). In conclusion, iGEMS is a robust methodol-
ogy for detection of AEU events using global transcriptome
data, yielding results with limited requirement for visual in-
spection and a high true positive rate. Our meta-analysis
indicates that RNA-seq protocols do not provide sufficient
quantification of much of the transcriptome (‘read cover-
age’), which limits alternative splicing analysis of RNA-seq
data to only the highest abundance transcripts.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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